Cargando…
Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan
BACKGROUND: A rare muscle disease, GNE myopathy is caused by mutations in the GNE gene involved in sialic acid biosynthesis. Our recent phase II/III study has indicated that oral administration of aceneuramic acid to patients slows disease progression. METHODS: We conducted a phase III, randomized,...
Autores principales: | Mori-Yoshimura, Madoka, Suzuki, Naoki, Katsuno, Masahisa, Takahashi, Masanori P., Yamashita, Satoshi, Oya, Yasushi, Hashizume, Atsushi, Yamada, Shinichiro, Nakamori, Masayuki, Izumi, Rumiko, Kato, Masaaki, Warita, Hitoshi, Tateyama, Maki, Kuroda, Hiroshi, Asada, Ryuta, Yamaguchi, Takuhiro, Nishino, Ichizo, Aoki, Masashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416530/ https://www.ncbi.nlm.nih.gov/pubmed/37568154 http://dx.doi.org/10.1186/s13023-023-02850-y |
Ejemplares similares
-
Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan
por: Suzuki, Naoki, et al.
Publicado: (2023) -
Nationwide patient registry for GNE myopathy in Japan
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2014) -
Multidimensional analyses of the pathomechanism caused by the non-catalytic GNE variant, c.620A>T, in patients with GNE myopathy
por: Yoshioka, Wakako, et al.
Publicado: (2022) -
Long-term evaluation parameters in GNE myopathy: a 5-year observational follow-up natural history study
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2022) -
GNE genotype explains 20% of phenotypic variability in GNE myopathy
por: Pogoryelova, Oksana, et al.
Publicado: (2019)